Sociedad Americana de Hirudoterapia

Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent

Case report published in Clinical Case Reports (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportEnsayos clínicosDesarrollo de fármacosMele M et al. · Clinical Case Reports, 2020

Abstract

In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory diagnosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Resumen

Case demonstrating that bivalirudin can be a pragmatic empiric choice for unexplained post-PCI coronary thrombosis suspicious for HIT, even before laboratory confirmation of anti-PF4 antibodies.

Por qué esto importa para la hirudoterapia

This article advises that heparin-induced thrombocytopenia (HIT) should always be considered in cases of unexplained post-PCI coronary thrombosis, and suggests that a pragmatic approach with bivalirudin may be reasonable even without confirmed laboratory diagnosis. The abstract discusses bivalirudin as an alternative anticoagulant in this clinical context but provides no detail on its pharmacological origin or relationship to hirudin or leech-derived substances. There is no mention of leeches, leech therapy, or the leech secretome anywhere in the abstract. Accordingly, this article has no defensible or direct relevance to ASH's domain of hirudotherapy or the leech secretome; any connection would be speculative and unsupported by the source text.

Citación

Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.

Mele M et al. · Clinical Case Reports, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.